Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis

Journal of the American College of Cardiology

Volumn 19, Issue 2, 1992, Pages 433-440

  Martin, Ulrich ^a   Sponer, Gisbert ^a   Strein, Klaus ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANISTREPLASE; RETEPLASE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY THROMBOSIS; DOG; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL;

ANIMAL; ANISTREPLASE; COMPARATIVE STUDY; CORONARY THROMBOSIS; DOGS; FEMALE; FIBRINOLYTIC AGENTS; MALE; RECOMBINANT PROTEINS; STREPTOKINASE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR;

EID: 0026595548     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(92)90501-D     Document Type: Article

References (37)

1. Double-blind randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction
2. Tissue plasminogen activator Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarction
3. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction
4. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
5. Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction
6. Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis
7. Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model
8. A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.)
9. Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS)
10. Effect of intravenous APSAC on mortality after acute myocardial inferction preliminary report of a placebo-controlled clinical trial
11. Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of anti-thrombotic agents
12. 2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog
13. Combination of the thromboxane receptor antagonist, sulotroban (BM 13.177; SK&F 95587), with streptokinase: demonstration of thrombolytic synergy
14. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma
15. Biochemische und physiologische Grundlagen zum Gewebe-Plasminogenaktivator (t-PA)
16. Production of a recombinant human tissue plasminogen activator variant (BM 06.022) from Escherichia coli using a novel renaturation technology (abstr)
17. Inhibition of factor XIIIa in a canine model of coronary thrombosis: effect on reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator
18. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation
19. D-Phe-ProArg-chloromethylketone: its potential use in inhibiting the formation of in vitro artifacts in blood collected during tissue-type plasminogen activator thrombolytic therapy
20. Standardized template bleeding time in dogs
21. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens
22. Plasminogen determination in human plasma
23. The mechanism of clot dissolution by plasmin
24. Quantitation of the plasma protease inhibitor antiplasmin with the chromogenic substrate
25. Bolus alteplase
26. Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the arg-glyaspcontaining peptide bitistatin in a canine model of coronary thrombosis
27. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin
28. Augmentation of streptokinaseinduced thrombolysis by heparin and prostacyclin
29. Pharmacokinetics and coronary thrombolytic properties of two human tissue-type plasminogen activator variants lacking the finger-like, growth factor-like, and first kringle domains (amino acids 6–173) in a canine model
30. Thrombolylic activity of a novel plasminogen activator, LY210825, compared with recombinant tissuetype plasminogen activator in a canine model of coronary artery thrombosis
31. Dose-dependent pharmacokinetics of recombinant tissue-type plasminogen activator in anesthetized dogs following intravenous infusion
32. Dose-ranging study of the novel recombinant plasminogen activacr BM 06.022 in healthy volunteers (abstr)
33. Pharmacokinetics of antigen and activity of recombinant tissue type plasminogen activator after infusion in healthy volunteers
34. Successful recanalisation of experimentally occluded coronary arteries in anesthetized dogs with recombinant single-chain tissue-type plasminogen activaor (sct-PA)
35. A canine model of coronary artery thrombosis with superimposed high grade stenosis for the investigation of rethrombosis after thrombolysis
36. The thrombolytic effects of native tissue-type plasminogen activator (AK-124) on experimental canine coronary thrombosis
37. Comparison of the effects of streptokinase, t-PA and APSAC on human platelet aggregation in vitro in the absence and presence of aspirin